HomeCare Guidelines

Care Guidelines

Duchenne Muscular Dystrophy Speech Delay: Understanding Language Development in Children with DMD

Duchenne muscular dystrophy speech delay is an important developmental concern that families and healthcare professionals should recognize. Although Duchenne muscular dystrophy (DMD) is primarily known as a genetic neuromuscular condition causing progressive muscle weakness, research has shown that some boys with DMD can also experience differences or delays in...

Guide to DMD for Parents and Teachers at School: A Complete Guide for Safety, Learning, Friendship and Inclusion

A well-structured guide to DMD for parents and teachers at school is essential for supporting children with Duchenne Muscular Dystrophy (DMD) in educational environments. DMD is a progressive neuromuscular condition that affects muscle strength, endurance, and sometimes cognitive functioning. These challenges directly influence how a child participates in school...
spot_img

Keep exploring

Ultimate Age-Specific Care Considerations in Duchenne Muscular Dystrophy for Families and Clinicians

Age-Specific care considerations in Duchenne muscular dystrophy are central to optimizing outcomes in individuals...

Best Physical Therapy Strategies for Duchenne Muscular Dystrophy

Physical therapy in Duchenne muscular dystrophy (DMD) is a cornerstone of comprehensive disease management,...

Occupational Therapy in Duchenne Muscular Dystrophy: Complete Guide to DMD Rehabilitation

Occupational therapy in Duchenne muscular dystrophy (DMD) plays a critical role in preserving independence,...

Hydrotherapy in Duchenne Muscular Dystrophy (DMD): Benefits, Exercises, and Clinical Evidence

Hydrotherapy in Duchenne Muscular Dystrophy (DMD)—also known as aquatic therapy, water-based rehabilitation, or pool-based...

Newly Diagnosed Patients with Duchenne Muscular Dystrophy: A Complete Family Guide

Newly diagnosed patients with Duchenne muscular dystrophy (DMD) and their families often find themselves...

Scoliosis in Duchenne Muscular Dystrophy: Detection, Exercises, and Surgical Treatment

Scoliosis in Duchenne Muscular Dystrophy is one of the most significant orthopedic complications associated...

Orton-Gillingham Approach in Duchenne Muscular Dystrophy: Benefits, Evidence & Applications

The Orton-Gillingham approach in Duchenne muscular dystrophy is gaining attention as families and clinicians...

Stress and Anxiety in Duchenne Muscular Dystrophy: Symptoms, Support & Treatment

Stress and anxiety in Duchenne muscular dystrophy (DMD) are increasingly recognized as critical yet...

Essential Knowledge About Learning Disabilities in Duchenne Muscular Dystrophy

Learning disabilities in Duchenne muscular dystrophy represent a critical yet often overlooked aspect of...

Managing Bone Fractures in Duchenne Muscular Dystrophy (DMD): Prevention, Risks & Treatment

Managing Bone Fractures in Duchenne muscular dystrophy (DMD) is a critical component of multidisciplinary...

Emergency Care in Duchenne Muscular Dystrophy: Life-Saving Strategies, Risks, and Clinical Guidelines

Emergency care in Duchenne muscular dystrophy (DMD) is a critical and often life-saving aspect...

Heart Health in Duchenne Muscular Dystrophy: Cardiomyopathy, Detection, and Modern Treatment Strategies

Heart health in Duchenne Muscular Dystrophy is a critical yet often underrecognized aspect of...

Latest articles

Entrada Therapeutics ENTR-601-45: Early Exon 45 Skipping Study Shows Increased Dystrophin Production

Entrada Therapeutics has announced positive initial results from its Exon 45 Skipping Study, ELEVATE-45-201,...

Entrada Therapeutics Advances ENTR-601-44 to 18 mg/kg in Its Duchenne Exon 44 Skipping Study

Entrada Therapeutics has received clearance to test the highest dose in its Exon 44...

Sapreme Therapeutics Reports Strong Preclinical Dystrophin Restoration With SPM-2551 in Duchenne

Sapreme Therapeutics has announced promising preclinical results for SPM-2551, an experimental treatment for Duchenne...

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Capricor Therapeutics has reported new results from the HOPE-3 study evaluating Deramiocel in people...

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Ractigen Therapeutics has presented positive first-in-human data for RAG-18 (NCT07282652), an investigational treatment for...

Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data

Entrada Therapeutics’ ENTR-601-44 is an investigational therapy designed for patients with Duchenne muscular dystrophy...

NS Pharma’s Brogidirsen Shows 5-Year Clinical Data in DMD Patients Amenable to Exon 44 Skipping

NS Pharma’s brogidirsen (NS-089/NCNP-02) is an investigational therapy for Duchenne muscular dystrophy (DMD) designed...

ELEVIDYS WMS 2026 Data: What They Show—and What They Don’t

Sarepta Therapeutics has presented new data on ELEVIDYS (delandistrogene moxeparvovec) at the 2026 World...